Akums Drugs and Pharmaceuticals Limited announced its financial performance for the quarter and year ended March 31, 2026, reporting a robust annual consolidated revenue of ₹43,590.17 million. The company’s board has recommended a final dividend of ₹1.00 and a special dividend of ₹2.00 per equity share, subject to shareholder approval. Additionally, the company confirmed key leadership changes and the schedule for its 22nd Annual General Meeting.
Financial Highlights
For the financial year ended March 31, 2026, Akums achieved a consolidated annual profit of ₹2,563.97 million. On a standalone basis, the company reported an annual revenue of ₹13,487.36 million. Despite minor operational challenges, the company continues to maintain a strong operational footprint.
Dividend Recommendations
Demonstrating its commitment to value creation for shareholders, the Board of Directors has recommended a final dividend of ₹1.00 per equity share (50%) and a special dividend of ₹2.00 per equity share (100%) for the financial year ending March 31, 2026. The record date to determine shareholder eligibility has been set for Friday, July 3, 2026.
Key Corporate Developments
The company announced significant updates, including:
- Leadership Changes: Mr. V. Jagannathan has been appointed as President – HR, while Mr. Arvind Srivastava has stepped down from the same role.
- Auditor Appointments: M/s. Balwinder & Associates have been re-appointed as Cost Auditors, and Mahajan & Aibara LLP have been appointed as Internal Auditors for the 2026-27 financial year.
- Annual General Meeting: The 22nd AGM is scheduled for July 10, 2026, at 11:00 AM IST via video conferencing.
IPO Proceeds Utilization
Akums provided a status update on its IPO fund utilization. Out of the ₹6,800 million raised, the company has successfully utilized ₹6,373.70 million as of March 31, 2026. The remaining funds are being deployed primarily for inorganic growth initiatives and general corporate purposes, consistent with the company’s long-term strategic objectives.
Source: BSE
